Products - Stomach cancer | Topic | NICE

Showing 5 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Suspected Cancer: recognition and referral (update)
Status:
In development | In consultation
Programme:
NICE guideline
Consultation end date:
2 February 2026
Expected publication date:
25 March 2026
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 September 2026
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC